Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial
Rakesh Popat(University College London Hospitals NHS Foundation Trust), Jamie Cavenagh(St Bartholomew's Hospital), Louise Flanagan(University of Leeds), Gordon Cook(University of Leeds), Matthew Streetly(St Thomas' Hospital), Bhuvan Kishore(National Health Service), Heather Oakervee(Barts Health NHS Trust), Sarah Brown(University of Leeds), Andrew Hall(University of Leeds), Eric Low(Myeloma UK), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Walter M. Gregory(University of Leeds)
Cited by 43
Related Papers
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564